00:11:18 EDT Sun 20 Aug 2017
Enter Symbol
or Name

Q:MJNA - MEDICAL MARIJUANA I - http://www.medicalmarijuanainc.com/00:11:18 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MJNA - Qnot subscribed0.1026-0.0018-1.74,275.34495710.10  0.1085  0.100.27  0.0416:02:24Aug 1715 min RT 2¢

Recent Trades - Last 10 of 571
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2017-08-17 09:00U:MJNANews ReleaseMedical Marijuana, Inc. to Exhibit Only Federally Legal Product, Zero-THC Real Scientific Hemp Oil ™, at ExpoWeed in Mexico City
2017-08-16 09:00U:MJNANews ReleaseVanity Fair Mexico Article Features Medical Marijuana, Inc. Subsidiary HempMeds ® Mexico's Role in Improving Lives of Thousands of Patients
2017-08-14 09:00U:MJNANews ReleaseMedical Marijuana, Inc. Subsidiary HempMeds ® Brasil To Hold Its Second Doctor Symposium on Medical Cannabis in Sao Paulo, Brazil
2017-08-08 09:00U:MJNANews ReleaseMedical Marijuana, Inc. Announces July 2017 as Largest Revenue Sales Month in Company History
2017-08-04 09:00U:MJNANews ReleaseMedical Marijuana, Inc. Subsidiary Kannaway ® Recognizes Second Brand Ambassador in Company History to Achieve International Director Title
2017-08-03 09:00U:MJNANews ReleaseMedical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis
2017-08-01 09:00U:MJNANews ReleaseMedical Marijuana, Inc. Subsidiary Kannaway ® Announces July 25, 2017 Largest Revenue Day in Company History
2017-07-31 09:00U:MJNANews ReleaseMedical Marijuana, Inc. Commends Senate Appropriations Committee Renewal of the Rohrabacher-Farr Amendment
2017-07-27 15:41U:MJNANews ReleaseMedical Marijuana, Inc. Subsidiary HempMeds ® Mexico Discusses Therapeutic Benefits of Cannabis During Annual International League Against Epilepsy Meeting
2017-07-27 09:00U:MJNANews ReleaseMedical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome